10x Genomics, Inc.
TXG
$18.81
$0.060.32%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 641.81M | 644.47M | 624.66M | 610.79M | 629.74M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 641.81M | 644.47M | 624.66M | 610.79M | 629.74M |
| Cost of Revenue | 199.62M | 196.19M | 197.65M | 196.00M | 210.13M |
| Gross Profit | 442.19M | 448.28M | 427.01M | 414.78M | 419.61M |
| SG&A Expenses | 330.92M | 337.97M | 348.30M | 343.24M | 338.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 776.28M | 788.87M | 806.25M | 803.24M | 806.16M |
| Operating Income | -134.46M | -144.41M | -181.59M | -192.46M | -176.42M |
| Income Before Tax | -73.09M | -79.33M | -153.40M | -177.70M | -175.92M |
| Income Tax Expenses | 3.23M | 5.27M | 3.63M | 4.93M | 6.63M |
| Earnings from Continuing Operations | -76.32 | -84.60 | -157.04 | -182.63 | -182.55 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -76.32M | -84.60M | -157.04M | -182.63M | -182.55M |
| EBIT | -134.46M | -144.41M | -181.59M | -192.46M | -176.42M |
| EBITDA | -99.58M | -110.85M | -146.88M | -156.58M | -139.57M |
| EPS Basic | -0.62 | -0.70 | -1.30 | -1.52 | -1.53 |
| Normalized Basic EPS | -0.59 | -0.63 | -0.84 | -0.91 | -0.80 |
| EPS Diluted | -0.62 | -0.70 | -1.30 | -1.52 | -1.53 |
| Normalized Diluted EPS | -0.59 | -0.63 | -0.84 | -0.91 | -0.80 |
| Average Basic Shares Outstanding | 493.46M | 488.69M | 485.00M | 481.79M | 478.76M |
| Average Diluted Shares Outstanding | 494.21M | 489.45M | 485.00M | 481.79M | 478.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |